ReferenceID 6433
Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer's Disease Mouse Model
Oxid Med Cell Longev
Alzheimer's disease (AD) is the most common neurodegenerative disease nowadays that causes memory impairments. It is characterized by extracellular aggregates of amyloid-beta (Abeta), intracellular aggregates of hyperpho
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 6433
- Evidence Id
- 23023
- Core Evidence Id
- 23023
- Source Reference Id
- 6145
- Herb2 Reference Id
- HBREF006942
- Subject Paper Key
- HBIN047106_34777683
- Pubmed Id
- 34777683
- Doi
- 10.1155/2021/3298400
- Paper Title
- Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer's Disease Mouse Model
- Paper Abstract
- Alzheimer's disease (AD) is the most common neurodegenerative disease nowadays that causes memory impairments. It is characterized by extracellular aggregates of amyloid-beta (Abeta), intracellular aggregates of hyperphosphorylated Tau (p-Tau), and other pathological features. Trilobatin (TLB), a natural flavonoid compound isolated from Lithocarpuspolystachyus Rehd., has emerged as a neuroprotective agent. However, the effects and mechanisms of TLB on Alzheimer's disease (AD) remain unclear. In this research, different doses of TLB were orally introduced to 3xFAD AD model mice. The pathology, memory performance, and Toll-like receptor 4- (TLR4-) dependent inflammatory pathway protein level were assessed. Here, we show that TLB oral treatment protected 3xFAD AD model mice against the Abeta burden, neuroinflammation, Tau hyperphosphorylation, synaptic degeneration, hippocampal neuronal loss, and memory impairment. The TLR4, a pattern recognition immune receptor, has been implicated in neurodegenerative disease-related neuroinflammation. We found that TLB suppressed glial activation by inhibiting the TLR4-MYD88-NFkappaB pathway, which leads to the inflammatory factor TNF-alpha, IL-1beta, and IL-6 reduction. Our study shows that TLR4 might be a key target of TLB in AD treatment and suggests a multifaceted target of TLB in halting AD. Taken together, our findings suggest a potential therapeutic effect of TLB in AD treatment.
- Journal
- Oxid Med Cell Longev
- Publish Year
- 2021
- Experiment Subject
- mouse
- Experiment Type
- Animal Experiment
- Phenotype Related
- Neuroinflammation; Alzheimer's Disease; Memory Impairment; Synaptic Degeneration; Neurodegenerative Disease; Memory Impairments; Hippocampal Neuronal Loss
- Paper Title Cn
- Paper Title En
- Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer's Disease Mouse Model
- Bilingual Status
- semi_complete